Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer.

摘要: 1015Background: For MBC patients with isolated brain progression, current guidelines recommend treatment CNS-directed therapy and continuation of systemic therapy, although there are limited data evaluating this strategy. Two Phase 1b trials tucatinib permitted HER2+ to continue study following in instances metastases (BM) progression. Methods: 2 studies were pooled identify progression (defined as new or progressive BM stable responding disease) while on study. In treated for the median time any subsequent death was determined. Results: 117 analyzed, 57 004 (tucatinib + T-DM1) 60 005 +/- trastuzumab capecitabine) trials. 25 (21%) identified comprised groups: 14 who discontinued 11 continued treatm...